DrugPatentWatch Database Preview
Litigation Details for WATSON LABORATORIES, INC. v. SEBELIUS (D.C. 2012)
» See Plans and Pricing
WATSON LABORATORIES, INC. v. SEBELIUS (D.C. 2012)
| Docket | Start Trial | Date Filed | 2012-08-15 |
| Court | District Court, District of Columbia | Date Terminated | |
| Cause | 05:702 Administrative Procedure Act | Assigned To | Amy Berman Jackson |
| Jury Demand | None | Referred To | |
| Parties | KATHLEEN SEBELIUS; MARGARET A. HAMBURG; UNITED STATES FOOD AND DRUG ADMINISTRATION; WATSON LABORATORIES, INC. | ||
| Patents | 6,150,383; 6,150,384; 6,166,042; 6,166,043; 6,172,090; 6,211,205; 6,271,243; 6,303,640; 6,329,404 | ||
| Attorneys | Aaron J. Feigenbaum; Chad A Landmon; Drake S. Cutini; Margaret L. Woodland; Mark D. Alexander; Nicholas E.O. Gaglio | ||
| Firms | Axinn Veltrop Harkrider LLP; Axinn, Veltrop & Harkrider LLP; DEPARTMENT OF JUSTICE, Consumer Protection Branch; Margaret L. Woodland | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in WATSON LABORATORIES, INC. v. SEBELIUS
The small molecule drugs covered by the patents cited in this case are Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , Start Trial , and Start Trial .
Details for WATSON LABORATORIES, INC. v. SEBELIUS (D.C. 2012)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2012-08-15 | 1 | pioglitazone’s use as a combination therapy (U.S. Patent Nos. 6,150,383, 6,150,384, 6,166,042, 6,166,043, 6,172,090…U.S. Patent Nos. 5,965,584 and 6,329,404) (collectively, the “Composition Patents”) and patents relating…name drug manufacturer should submit patent information – the patent’s number and its expiration date –…manufacturer has not filed patent information with FDA; or, for each patent listed in the Orange Book …seeking approval, (ii) that the patent has expired; (iii) that the patent expires on a date before which | External link to document | |
| 2012-10-22 | 53 | ; 6,172,090; 6,150,383; and 6,150,384. Brannan Decl. ¶ 11. Watson refers to these patents as “Combination… IV Composition/Use 6,150,383 Use-only IV … IV Composition/Use 6,150,383 Use-only viii … Combination Therapy Patents.”). 4 The use-only patents are U.S. Patent Nos. 6,211,205; 6,271,243…Combination Therapy” patents. Id. 5 The drug composition/use patents are U.S. Patent Nos. 5,965,584 and | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
